Dupilumab for treating bullous pemphigoid [ID6479]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC